Cancer Therapeutics
Targeting lactate metabolism for cancer therapeutics
... Genetic knockdown studies and the development of several small-molecule inhibitors have established the relevance of tar- geting lactate transporters in cancer therapeutics. Knockdown of MCT1 (and in some ...
9
Mechanisms of resistance to ErbB targeted cancer therapeutics
... The ErbB receptors, such as EGFR, have been intensely pursued as targets for cancer therapeutics. However, a large percentage of patients who are initially responsive to ErbB- targeted therapies experience ...
5
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
... for cancer therapeutics, because of their role in regulating critical cell cycle checkpoints and ...for cancer versus normal tissue and are not well tolerated at doses required for ...
88
A Review on Cuminosides Nanomedicine-: Pharmacognostic approach to Cancer therapeutics
... We provide a schematic layout which proposes the basis upon which cuminosides nanoformulations can be selected for future clinical application or clinical trials (Figure 4). Liposomal formulations of drugs (Doxil, ...
11
FOLATE CONJUGATES: A BOON IN THE ANTI CANCER THERAPEUTICS
... Future Directions and Concluding Remarks: Receptor targeted drug delivery can claim two advantages over non targeted therapies depending on the nature of targeting ligand and properties of therapeutic cargo: 1) receptor ...
26
Digitoxin and its analogs as novel cancer therapeutics
... [67,68]. Digitoxin is a cardiotonic drug with a narrow therapeutic window; thus, toxicity is a persistent con- cern whenever digitoxin is considered for therapy [69]. Cardiotoxicity is frequently encountered as the most ...
10
<p>Smart Targeting To Improve Cancer Therapeutics</p>
... Abstract: Cancer is the second largest cause of death worldwide with the number of new cancer cases predicted to grow signi fi cantly in the next ...improve cancer diagnosis and treatment ef fi ...
20
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
... lung cancer caused by doxycycline-induced over-expression of a double mutant EGFR ...breast cancer, non-small cell lung cancer, ovarian cancer and other solid tumor ...
15
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
... cancer, gastric cancer, and head and neck squamous cell carcinoma [36]. Two hundred and seventy-seven pa- tients were enrolled and received intravenous atezolizu- mab every 3 weeks (q3w) at doses of 10, 15, ...
13
Synthetic lethality: a framework for the development of wiser cancer therapeutics
... oncogenes. Cancer-relevant KRAS mutations lead to loss of K-Ras GTPase activity, leading to constitutive ...colorectal cancer lines that did or did not harbor an oncogenic KRAS mutation with approximately ...
6
Targeting microenvironment in cancer therapeutics
... of cancer cells) of the stroma through enzymatic destruction of hyaluronan, could reduce interstitial pressure and improve vessel patency and ...pancreatic cancer (PC) ...colon cancer, CXCR4 is ...
9
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
... breast cancer (MBC) patients who had received prior aromatase-inhibitor therapy in a phase I study ...breast cancer after failure of aromatase inhibitor alone or aromatase inhibitor plus mTOR inhibitor ...
17
HDAC INHIBITORS: A NEW ARMOUR IN ANTI-CANCER THERAPEUTICS
... Beyond cancer there may be several novel therapeutic areas where HDACi may provide therapeutic benefits. Early in the investigations on HDAC inhibitors it was recognized that one of the effects was the activation ...
10
Upconversion Nanoparticles for Photodynamic Therapy and Other Cancer Therapeutics
... Different from PDT, photothermal therapy is another type of photo therapies that utilizes NIR ab- sorbing agents to generate heat from absorbed light to ‘cook’ cancer by high temperature. In our group, we ...
14
Scope of nanotechnology in ovarian cancer therapeutics
... Magnetic nanoparticle based micelles act as drug car- riers as well as external magnetic field guides in cancer therapy treatments [87]. Developing micelle-magnetic nanoparticles is a promising alternative. ...
10
DNA Nanotechnology for Cancer Therapeutics
... The delivery of drug molecules specifically to the tumor site is an exigent requirement to avoid side effects during cancer therapy. However, this requirement is still clinically unmet, mainly due to the lack of ...
16
Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage
... pancreatic cancer cells To evaluate the anti-pancreatic cancer potential of ruthenium complexes and possible universal anti-cancer therapeutics, human pancreatic cancer cell line PANC ...
11
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
... Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Molecular cancer therapeutics[r] ...
34
Formulation and Evaluation of Polymeric Nanoparticles as Carriers of Rosuvastatin Calcium for Oral Administration
... Table IV Applications of various nanosystems in cancer therapy Nanosystem Applications in cancer therapeutics Carbon nanotubes DNA mutation detection, disease protein biomarker detection[r] ...
283
The Role of Nanomedicine in Cell Based Therapeutics in Cancer and Inflammation
... based therapeutics is one of the most rapidly advancing medical fields, bringing together a range of fields including transplantation, tissue engineering and regeneration, biomaterials and stem cell ...cell-based ...
12